Kornimate/medical-research-clean huggingface dataset:
kinect-based versus tablet-based cognitive training: a pilot study with psychiatric patients

Conditions: Psychiatric Disorder

Summary: this study aims to analyze which cognitive training experimental condition - tablet versus kinect - results in greater cognitive, mood, quality of life, and functional gains in a sample of chronic psychiatric patients.

cognitive deficits are a nuclear feature of several psychiatric disorders, leading to a decrease in functional abilities and quality of life. besides facilitating the inclusion of more ecologically valid stimuli and training tasks, technology-based cognitive training methods allow more dynamic interactions with the cognitive training content, which can result in an enhancement of patients' motivation and engagement in the therapeutic process. the modality of interaction with the cognitive training content may influence patients' response to cognitive training interventions. for instance, cognitive training through the tablet requires essentially hand movements (e.g., interaction with the training tasks by touching the correct stimuli), while cognitive training through the kinect involves the performance of wide range movements (e.g., interaction with the training tasks by making specific "body" movements to select the correct stimuli). this study aims to analyze which cognitive training experimental condition - tablet versus kinect - results in greater cognitive, mood, quality of life, and functional gains in a sample of chronic psychiatric patients.

Eligibility criteria:
inclusion criteria: * psychiatric diagnosis; * maximum age: 75 years old; * relatively preserved language abilities (expressive and receptive language); * being able to read and write; * having no motor limitations; * having no medical history of neurological conditions (e.g., stroke, traumatic brain injury, multiple sclerosis, etc.) * preserved visual and auditory acuity; exclusion criteria: * experiencing an acute psychiatric episode.

Keywords: cognitive training simulations of instrumental activities of daily living tablet-based cognitive training kinect-based cognitive training psychiatric disorders
contrast ultrasound perfusion imaging in peripheral arterial disease (pad)

Conditions: Peripheral Arterial Disease

Summary: contrast ultrasound is a technique that can quantify blood flow in the tissues of the body by ultrasound detection of microbubble contrast agents that behave in the circulation similar to red blood cells. in this study, the investigators hypothesize that contrast ultrasound of blood flow in the leg (thigh and calf) at rest and during stress produced by medications that mimic exercise (vasodilator stress) can provide information on the location and severity of peripheral vascular disease (blockages of the blood vessels in the leg). the investigators will also determine whether symptom improvement after revascularization (procedures to open up or bypass the blockages) is directly related to the improvement in blood flow.


Eligibility criteria:
inclusion criteria: 1. known or suspected pad 2. lower extremity angiography or mra planned or performed within 6 months exclusion criteria: 1. age \<19 y.o. 2. pregnant or lactating females 3. hypersensitivity to ultrasound contrast agent, dipyridamole, or regadenoson 4. severe reactive airways disease 5. evidence right-to-left shunt (identified on screening echo) 6. nyha class iii or iv heart failure. 7. planned amputation 8. unstable coronary artery disease or severe aortic stenosis
effect of higher doses of remifentanil on postoperative pain in patients undergoing thyroidectomy

Conditions: Nodular Goiter

Summary: extensive clinical studies have shown that intraoperative infusion high dose of remifentanil (0.2ug/kg/min) induced postoperative hyperalgesia. recent experimental study however suggests that higher dose of remifentanil may attenuate postoperative hyperalgesia. thus, the present study is designed as a "proof of principle" study and hypothesizes that higher dose of remifentanil may reduce postoperative pain in patients.

remifentanil, an ultra-short acting opioid, is widely used in the patients undergoing surgery. however, extensive studies report that remifentanil,administered at 0.2ug/kg/min or 0.4ug/kg/min intraoperatively, can result in postoperative hyperalgesia and increase the consumption of analgesics when compared with low dose (0.05ug/kg/min). however, a recent experimental study shows that large dose of remifentanil can inhibit pain hypersensitivity through erasing the spinal sensitization of pain. the present study thus hypothesizes that higher dose of remifentanil (1.2ug/kg/min) may attenuate postoperative pain. the present study will compare the effect of two different dose of remifentanil (0.2ug/kg/min and 1.2ug/kg/min) on postoperative pain. patients undergoing thyroidectomy will be recruited, and mechanical threshold will be measured in the remote region of surgical site preoperatively. the patients will be randomly divided by two groups, 0.2ug/kg/min (group i) and 1.2ug/kg/min (group ii). after operation, mechanical threshold and visual analogue scale (vas) will be measured as the indicators of postoperative pain. the consumption of morphine will also be compared between these two doses of remifentanil. the present study may find optimized dose of opioid usage in the patients undergoing surgery to relieve the postoperative pain.

Eligibility criteria:
inclusion criteria: * asa grade i or ii * age 18-60 years old * bmi\<35, exclusion criteria: * do not consent, * chronic pain, * used pain killer, * undergoing operation previously * diabetes or the other diseases affecting the sensory. * difficult intubation; * unexpected surgical complication such as bleeding; * psychiatric disorders; * drug or alchohol abuse

Keywords: remifentanil, opioid, hyperalgesia, visual analogue score thyroidectomy,
the chinese version of the american shoulder and elbow surgeons standardized shoulder assessment form questionnaire, patient self-report section: a cross-cultural adaptation and validation study

Conditions: Shoulder Pain

Summary: background: the patient self-report section of the american shoulder and elbow surgeons standardized shoulder assessment form (asesp) is one of the most validated and reliable assessment tools. this study aimed to establish a validated chinese version of asesp (asesp-ch). methods: a clinical prospective study was performed. following the guidelines of forward-backward translation and cross-cultural adaptation, a chinese version of asesp was established. patients older than 18 years with shoulder disorders were included. patients who could not complete test-retest questionnaires within the interval of 7-30 days and patients who received interventions were excluded. intraclass correlation (icc) was calculated for test- retest reliability, whereas internal consistency was determined by cronbach value. construct validity was evaluated by comparing the corresponding domains between the asesp-ch and a validated chinese version of 36-item short form health survey (sf-36).


Eligibility criteria:
inclusion criteria: * \[1\] patients' age ≥ 18 years * \[2\] patients with clear insights * \[3\] patients with any shoulder disorders * \[4\] patients who are able to speak and write in chinese * \[5\] patients who completed the questionnaires twice at an interval of 7 days to 30 days. exclusion criteria: * \[1\] the patient could not complete all of asesp-ch and sf-36 questionnaires * \[2\] the test-retest interval was less than 7 days or more than 30 days * \[3\] the patient received interventional procedures, such as shoulder injections or surgery, during the test-retest interval
pilot study in a company in maine-et-loire to evaluate the feasibility, acceptability, and impact on the participation rate of awareness of colorectal cancer screening by occupational health teams

Conditions: Colorectal Cancer

Summary: the main objective of this pilot study is to implement an awareness campaign for colorectal cancer screening in the workplace, in partnership with the staff of the occupational health service of one of the largest companies in maine-loire , and to evaluate the impact of this action on the participation rate of colorectal cancer screening among employees.


Eligibility criteria:
inclusion criteria: * the study population is made up of the employees of the chu d'angers included in the target population of organized colorectal cancer screening in the maine-et-loire so employees aged 50 and over. exclusion criteria: * the criteria for non-inclusion are those of organized screening for colorectal cancer taking into account the active population: * age \ 67 years * personal or family history of polyps or colorectal cancer * personal history of intestinal disease already undergoing colonoscopy surveillance (chronic inflammatory bowel disease, hnpcc syndrome, familial adenomatous polyposis) * known genetic disease with risk of developing colorectal cancer.
a study to evaluate the safety, tolerability, pharmacokinetic properties and immunogenicity of 9mw3811 in healthy subjects

Conditions: Idiopathic Pulmonary Fibrosis

Summary: this is a single ascending dose study of 9mw3811, the primary objective of which is to evaluate the safety and tolerability of 9mw3811 in healthy adult participants.


Eligibility criteria:
inclusion criteria: 1. male or female participants between 18 and 55 years of age, inclusive. 2. male body weight ≥50.0 kg, or female body weight ≥45.0 kg, and body mass index (bmi) between 18.0 and 26.0 kg/m2, inclusive. 3. in good health determined by the investigator based on a medical evaluation. exclusion criteria: 1. clinically significant histories determined by the investigator of cardiovascular, hepatic, renal, gastrointestinal, neurological, respiratory, hematological, endocrinological, immunological, metabolic, and musculoskeletal abnormalities. 2. having any history of an allergy to biological agents or any components of study drug; those who have a history of allergies and judged by the investigator to be ineligible for enrolment. 3. use of any prescription medication 14 days prior to dosing or over-the-counter medication, vitamins, and/or herbal medicines 7 days prior to dosing (excluding oral contraception, occasional paracetamol, ibuprofen and standard dose of multivitamins at the discretion of the pi or designee) 4. participants who have been vaccinated within 4 weeks prior to screening or who are scheduled to be vaccinated during the study 5. participants who received immunosuppressants except for previous use of inhaled or nasal corticosteroids 4 weeks earlier before administration or any oral corticosteroids 8 weeks earlier before administration, and who had received a single dose of monoclonal antibodies for any reason within 1 year prior to screening 6. participants with one or more clinically significant positive test results of hepatitis b surface antigen (hbsag), hepatitis c virus (hcv) antibody, treponema pallidum antibody or human immunodeficiency virus (hiv) antibody 7. history of active tuberculosis, or participants with active or latent tuberculosis infection during screening 8. history of drug abuse including narcotic and psychiatric drugs within 6 months prior to screening or a positive drug abuse test result at baseline (morphine, methamphetamine, tetrahydrocannabinol acid)
removal of massive subretinal organized blood clot with fragmatome

Conditions: Age-Related Macular Degeneration

Summary: by using the ultrasound power delivered by fragmatome, the hard, organized blood clot could be removed easily.


Eligibility criteria:
inclusion criteria: * patients with massive subretinal hemorrhage from age related macular degeneration * patients had organized subretinal blood clot were managed by inferior retinectomy. exclusion criteria: * patients without massive subretinal hemorrhage * patients were not age related macular degeneration.

Keywords: organized blood clot fragmatome exudative age related macular denegeration
an open label, multi-center, phase i clinical study to evaluate the safety, effectiveness and pharmacokinetic characteristics of sim1803-1a in patients with locally advanced/metastatic solid tumors with ntrk, ros1 or alk gene fusion mutations.

Conditions: Advanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion

Summary: this research study is done to test the safety, effectiveness and pharmacokinetic characteristics of sim1803-1a in patients with locally advanced/metastatic solid tumors with ntrk, ros1 or alk gene fusion mutations. the cancer must have a change in a particular gene (ntrk1, ntrk2, ntrk3, ros1 or alk). sim1803-1a is a drug that blocks the actions of these ntrk/ ros1 /alk genes in cancer cells and can therefore be used to treat cancer.


Eligibility criteria:
inclusion criteria: * adult patients with a locally advanced or metastatic solid tumor that has progressed or was nonresponsive to available therapies, are unfit for standard chemotherapy or for which no standard or available curative therapy exists；proof of a malignancy harboring a ntrk、ros1 or alk fusion；eastern cooperative oncology group (ecog) score of 0 or 1 and a life expectancy of at least 3 month；adequate hematologic, hepatic, and renal function；signed informed consent form； exclusion criteria: * any contraindications as listed in the local approved product information；patients with unstable primary central-nervous-system tumors or metastasis, exceptions possible；pregnancy or lactation；clinically significant active cardiovascular disease or history of myocardial infarction；participation in an investigational program with interventions outside of routine clinical practice；prior treatment with other kinase inhibitor with tropomyosin receptor kinase inhibition；active uncontrolled systemic bacterial, viral, or fungal infection；current treatment with a strong cyp3a4 inhibitor or inducer；
pilot pragmatic randomized controlled trial: horticultural therapy for inpatient older adults in an acute care hospital

Conditions: Frailty; Hospitalism

Summary: this study aims to investigate the feasibility and effectiveness of horticultural therapy (ht) on engagement, mood, and quality of life (qol) of older adults in geriatric acute care in singapore. investigators will also assess the effectiveness of ht on mobility and hospitalisation experience. this pilot study could inform how ht can be implemented in geriatric acute care and its effect on hospitalisation experience and recovery of function.

horticultural therapy (ht) is a non-pharmacological treatment utilizing plant-related activities as a form of alternative medicine to achieve specific goals that lead to person's well-being. geriatric patients in acute care wards are at risk of functional decline related to acute illness and prolonged bed rest during hospitalization. ht can complement medical treatment to ameliorate the adverse effects of hospitalisation in older adults. there is evidence that ht can improve the physical and psychological well-being of the older adults in different settings. the beneficial effects of ht have mostly been documented in nursing homes, community rehabilitation facilities and senior activity centres, but not in geriatric acute care settings. there is also a need to harness available knowledge and implement it where appropriate. this study aims to investigate the feasibility and effectiveness of ht on engagement, mood, and quality of life (qol) of older adults in geriatric acute care in singapore. investigators will also assess the effectiveness of ht on mobility and hospitalisation experience. this pilot study could inform how ht can be implemented in geriatric acute care and its effect on hospitalisation experience and recovery of function.

Eligibility criteria:
inclusion criteria: * 70 years old and above * an inpatient in khoo teck puat hospital * able to understand simple instructions (with abbreviated mental test's score of 6 and above) * have stable vital signs - blood pressure, heart rate and peripheral capillary oxygen saturation - to take part in horticultural therapy activities exclusion criteria: * on contact or droplet precaution * diagnosed with severe auditory-visual impairments * have major depressive disorder * have endocrine disorders * on steroid-based medications such as asthma and allergies that might affect the salivary cortisol level * on the dangerously ill list

Keywords: horticultural therapy randomized controlled trial
the impact of three distinct exercise types on fatigue, anxiety, and depression in parkinson's disease

Conditions: Parkinson Disease

Summary: the purpose of the study is to learn about the impact of exercise on fatigue, anxiety, and depression in parkinson's disease. it is well established that exercise improves the motor symptoms of parkinson's disease. however, it is not clear which types of exercise are most beneficial for specific non-motor symptoms.

this is a multi-site trial (12 patients in each site). the investigators are recruiting 24 patients who will be randomized into either a spinning class, yoga class, dance class, or no exercise intervention. classes will be conducted twice a week for 6 weeks total at times convenient for the patients. patients will also be asked to complete questionnaires after exercise classes to see if the exercise intervention improves measures of fatigue, anxiety, and depression - and what exercise intervention may be superior. all participants will be asked to complete questionnaires each week and will be asked to wear a "microsoft exercise band" during the course of the study. use of the exercise band is optional.

Eligibility criteria:
inclusion criteria: 1. subjects diagnosed with idiopathic parkinson's disease 2. age between 18 - 75 years 3. hoehn and yahr stage less than or equal to 3 4. mini-mental state exam (mmse) score of over 23 at screening 5. if subjects are taking any medications for depression, fatigue, or anxiety, regimen must be stable for 8 weeks prior to baseline visit 6. subjects willing and able to give informed consent exclusion criteria: 1. subjects with a diagnosis of an atypical parkinsonism 2. subjects unwilling or unable to obtain health waiver from primary care provider 3. score of 60 or more on updrs iii at screening 4. scores in the 'normal' range on all three study assessments: beck depression index ii, fatigue severity scale, and zung self-rating anxiety scale 5. participation in any of the 3 physical activities more than 3 times in the past for 8 weeks prior to baseline 6. any other reason that, in the investigator's opinion, would exclude the subject from participation in the study

Keywords: parkinson's disease fatigue anxiety depression exercise
tens of mens for rotator cuff tear

Conditions: Rotator Cuff Tear

Summary: the aim of this study was to clarify the effectiveness of physiotherapeutic intervention through the tens or mens in conjunction with kinesiotherapy in patients with partial thickness rotator cuff tear.

the primary characteristic of a rotator cuff tear is pain, while muscle weakness appears as a secondary feature, leading to further disability. the aim of this study was to clarify the effectiveness of physiotherapeutic intervention through the tens or mens in conjunction with kinesiotherapy in patients with partial thickness rotator cuff tear.

Eligibility criteria:
inclusion criteria: * patients suffering shoulder pain because of partial thickness rotator cuff tear, confirmed with mri and ultrasound scanning. * patients not receiving any recent pharmacotherapy with nsaids during the last month, or surgery at the shoulder area at any time point, * the referral orthopedic had suggested physiotherapy. exclusion criteria: * patients with open wounds or skin diseases in the shoulder area * pregnant women * patients with any type of neoplastic disease * patients with pacemakers or serious cardiovascular diseases including arrhythmia, - patients with collagen diseases * history of shoulder surgery
4d-125 in patients with x-linked retinitis pigmentosa (xlrp)

Conditions: X-Linked Retinitis Pigmentosa

Summary: this is a phase 1/2 multicenter study with two parallel parts: an observational natural history cohort and an open-label, prospective interventional trial in males with non-syndromic x-linked retinitis pigmentosa (xlrp) due to mutations in the gene encoding retinitis pigmentosa gtpase regulator (rpgr).

this phase 1/2 study will gather data in an observational phase natural history cohort to further characterize and evaluate natural disease progression in male patients with genetically-confirmed x-linked retinitis pigmentosa (xlrp) caused by mutations in the gene encoding retinitis pigmentosa gtpase regulator (rpgr). the study will also evaluate the safety and tolerability, as assessed by frequency and severity of ocular and systemic adverse events, as well as preliminary clinical efficacy of a single intravitreal (ivt) injection of 4d-125 at two dose levels in this patient population in one or both eyes (the contralateral eye dose provided the subject is eligible and provides consent). 4d-125 has been developed as a gene replacement therapy for xlrp. after receiving 4d-125, patients will be followed for 24 months with continued safety follow-up and 36 additional months of long-term follow-up. secondary endpoints will assess preliminary efficacy measures over time after 4d-125 administration.

Eligibility criteria:
natural history key inclusion criteria: * male, ≥ 6 years of age at the time of informed consent * hemizygous non-syndromic rpgr mutation confirmed by genetic testing interventional key inclusion criteria: * male, ≥12 years of age * hemizygous non-syndromic rpgr mutation confirmed by genetic testing * phase 1 dose exploration: at least one eye amenable to ivt injection and bcva ≤ 78 etdrs letters (\~20/32) and ≥ 34 etdrs letters (\~20/200) * phase 2 dose expansion: at least one eye amenable to ivt injection and both eyes must have bcva ≥ 34 etdrs letters (\~20/200) key exclusion criteria (all cohorts) * patient has previously received any aav treatment * pre-existing eye conditions or surgical complications that would preclude participation in an interventional clinical trial or interfere with the interpretation of study endpoints

Keywords: xlrp gene therapy
a comparison of the effects of aleglitazar and actos on renal function on patients with type 2 diabetes.

Conditions: Diabetes Mellitus Type 2

Summary: this 2 arm study will compare the effects of aleglitazar and actos, added to preexisting oral antihyperglycemic therapy and/or diet and exercise, on renal function in patients with type 2 diabetes, and normal or mildly impaired renal function. eligible patients will be randomized to receive either aleglitazar 0.6mg p.o. or actos 45mg p.o. daily. renal function and efficacy parameters will be assessed at intervals during the treatment period. the anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.


Eligibility criteria:
inclusion criteria: * adult patients, 18-75 years of age; * type 2 diabetes for \>=1 month; * drug naive, or receiving stable oral antihyperglycemic medication; * hba1c 6.5-10.0% at screening. exclusion criteria: * type 1 diabetes; * current or previous treatment with insulin; * history of renal disease other than diabetic nephropathy; * uncontrolled hypertension; * clinically significant cardiovascular disease; * congestive heart failure (chf) new york heart association (nyha) 3-4.